Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

BACKGROUND: Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Chittoria, Namita, Haddad, Housam, Elson, Paul, Tannir, Nizar M., Wood, Laura S., Dreicer, Robert, Garcia, Jorge A., Rini, Brian I., Jonasch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810513/
https://www.ncbi.nlm.nih.gov/pubmed/27026229
http://dx.doi.org/10.1186/s12885-016-2282-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810513/
https://www.ncbi.nlm.nih.gov/pubmed/27026229
http://dx.doi.org/10.1186/s12885-016-2282-5

Ejemplares similares